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Inhibition  of Ras-stimulating  enzymes is a possible  avenue to  treat  Ras-driven  diseases.  In this  issue of 
Chemistry & Biology, Evelyn and coworkers  report an inhibitor  for one such enzyme, Sos1, capable of 
impairing wild-type  Ras signaling in cells. 
 
H-, K-, and N-Ras toggle between ‘‘off’’ (GDP-bound) and ‘‘on’’ (GTP-bound) states during signal transduction. 
This cycle is controlled by guanine exchange factors (GEFs) and GTPase-activating proteins (GAPs) that 
catalyze the stimulation (Figure 1A, point a) and inactivation (Figure 1A, point b) of Ras proteins, respectively. 
GTP-bound Ras proteins bind to phosphatidylinositol 3-kinase a (PI3Ka), Raf kinases, and other effectors, 
leading to signaling diversification and amplification events in stimulated cells. This regulation is broken by 
mutations that generate oncogenic proteins deficient in GTP hydrolysis, overexpression of wild-type Ras 
(RasWT) proteins, inactivation of GAP-encoding genes, or deregulated upstream signaling elements (Figure 1A). 
Due to their frequent occurrence in human tumors, most drug discovery efforts have focused on mutant Ras 
(RasMUT) proteins and key downstream elements (Stephen et al., 2014). However, for pathologies exhibiting 
high amounts of RasWT signaling, targeting wild-type GTPases could be a therapeutically interesting option. The 
spectrum of RasWT-dependent diseases might be even larger than currently appreciated, because recent 
reports have unveiled key roles for H- and N-RasWT in RasMUT- driven tumorigenesis. Such functions include 
the generation of outbursts of Raf and PI3Ka signaling in mitogen-stimulated cancer cells (Figure 1A, point c) 
(Young et al., 2013), the dampening of K-RasMUT signals to avoid activation of the DNA damage response 
(Figure 1A, point d) (Grabocka et al., 2014), and, possibly the engagement of nonoverlapping effectors (Figure 
1A, point e) (Stephen et al., 2014). RasWT proteins are also implicated in signaling compensatory effects elicited 
by anti-Ras therapies, such as the stimulation of Ras pathways caused by the loss of the MEK-mediated 
inhibition of the EGF receptor typically observed when using MEK inhibitors (Figure 1A, point f) (Young et al., 
2013). An inference from these studies is that inhibitors of the Ras GDP/ GTP exchange reaction can represent, 
either singlehandedly or combined with other treatments, a potential therapeutic avenue for diseases featuring 
deregulated Ras activity. Up to now, the search for such inhibitors has been focused on Ras-binding compounds 
promoting GTPase conformations incompatible with GEF interactions. This approach has led to the isolation of 
compound families that recognize pockets located in the vicinity of the two Ras switch domains, the regions that 
mediate the Ras-GEF interaction. However, these molecules lack commercial interest because of low potency 
and inappropriate pharmacochemical features (Wang et al., 2012). Given that these molecules have to interact at 
1:1 ratios with Ras proteins to promote noticeable inhibitory effects, it is unlikely that this strategy will yield drugs 
with good therapeutic indexes. A more efficient alternative might be the use of drugs against the catalytic activity 
of Sos1, the Ras GEF in charge of stimulating RasWT proteins downstream of most receptors, RasMUT 
GTPases, and oncogenic protein tyrosine kinases (Jeng et al., 2012; Qian et al., 2000). This GEF is regulated by 
both receptormediated plasma membrane tethering steps (Figure 1A, point g) and an allosteric effect induced by 
the binding of active Ras molecules to a regulatory Sos1 domain (Figure 1A, h points) (Cherfils and Zeghouf, 
2013). In this issue of Chemistry & Biology, Evelyn et al. (2014) report the in silico screen-based isolation of an 
inhibitor (NSC658497) directed against a structural pocket located in the Sos1 catalytic domain (Figure 1B, site 
a). This site was a good pick in hindsight, because the binding of chemicals to a second Sos1 pocket causes 
increased catalytic rates (Burns et al., 2014) (Figure 1B, site b). As expected, NSC658497 blocks the interaction 
of Sos1 with RasWT proteins, Sos1 enzyme activity, and Ras signaling in both mitogen-stimulated and 
hyperactive Sos1 mutant-expressing cells. Although not tested, the in vivo effects of the inhibitor are probably 
mediated by the concurrent inactivation of the highly related Sos2 protein. This compound cannot bind to 
versions of the Sos1 catalytic domain carrying mutations in the putative drug-binding site, thus confirming its 
mechanism of action. In contrast to earlier data using Sos1- and RasWT-depleted cells (Grabocka et al., 2014; 
Jeng et al., 2012), Evelyn et al. (2014) find no overt effect of NSC658497 in the fitness of K-RasMUT-expressing 
cancer cells. This suggests that the inhibitor may not have enough potency to block the K-RasMUT-mediated 
allosteric activation of Sos1 (Jeng et al., 2012) or, alternatively, that the K-RasMUT cell lines utilized in the 
present study stimulate RasWT proteins using GEF-independent mechanisms. To clarify this discordance, it 
would be important to investigate the effect of NSC658497 in the Sos1-and RasWT-dependent cancer cell lines 
used in previous studies (Grabocka et al., 2014; Jeng et al., 2012), expand these analyses to larger numbers of 
RasMUT-expressing cancer cells, and verify whether the K-RasMUT-expressing cell lines used in the present 
work are actually Sos1-dependent. Other therapeuticallyinteresting studies to carry out in the near future include 
the analysis of NSC658497 in protein tyrosine kinasedependent transformation processes (Qian et al., 2000), its 
synergism with currently available anti-Ras pathway drugs (Young et al., 2013), and validation in animal models. 
Tackling these issues will help foresee the pharmacological potential and spectrum of applications of this inhibitor 
and subsequent derivatives. The therapeutic viability of this avenue has yet to be explored. The potency of 
NSC658497 is low in cells, indicating that further optimization steps will be needed. The eventual applicability of 
these compounds will also depend on in vivo pharmacokinetic behavior, therapeutic efficacy, toxicity, and side 
effects directly derived from the inactivation of Sos proteins in healthy tissues. The latter problem requires special 
attention here, because genetic analyses indicate that the concurrent inactivation of Sos1 and Sos2 causes lethal 
effects in adult mice (Baltanás et al., 2013).  
These problems should not occur when using Sos1-specific inhibitors, as inferred by the viability shown by mice 
lacking Sos1 in postnatal periods (Baltanás et al., 2013). Regardless of these potential caveats, this work 
highlights the feasibility of isolating Ras GEF-specific inhibitors, 
opens the door to new therapeutic opportunities in Sosdependent diseases, and provides a valuable tool to 
further address Sos function in cells. 
 
 
 
 
 
 
Figure 1. Therapeutic Targeting of Sos1 in Ras-Dependent 
Diseases 
 
(A) Ras regulatory cycle and Sos1-mediated crosstalk established 
between RasWT- (green) and K-RasMUT-regulated  (red) pathways. 
Red asterisks indi- cate genetic alterations that lead to the spurious 
activation of RasWT proteins. Other signaling crosstalk are not shown 
for the sake of simplicity. PTK, protein tyrosine kinase (membrane 
anchored or cytosolic). 
 
(B) Binding sites of inhibitory (site a, red) and stimulatory (site b, brown) 
com- pounds of Sos1 enzyme activity in one of the subregions of the 
Sos1 catalytic site. Sos1 residues potentially involved in the interaction 
with these com- pounds are shown in stick form and labeled. The Ras 
switch II region is shown in blue. The Sos1 aH helix that gets into a cleft 
between the switch regions and that is critical for the exchange 
reaction is not shown. N and C, N- and C- termini of the Sos1 
fragment shown. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1600   Chemistry & Biology 21, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 
